Synthesis and characterization of β-glucogallin as an aldose reductase inhibitor from Emblica officinalis

Planta Medica ◽  
2012 ◽  
Vol 78 (11) ◽  
Author(s):  
J Ponder ◽  
JM Petrash ◽  
DV LaBarbera
Keyword(s):  
Aldose Reductase ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor ◽  
Synthesis And Characterization ◽  
Emblica Officinalis

scholarly journals The Isolation and Characterization of β-Glucogallin as a Novel Aldose Reductase Inhibitor from Emblica officinalis

PLoS ONE ◽  
2012 ◽  
Vol 7 (4) ◽  
pp. e31399 ◽  
Author(s):  
Muthenna Puppala ◽  
Jessica Ponder ◽  
Palla Suryanarayana ◽  
Geereddy Bhanuprakash Reddy ◽  
J. Mark Petrash ◽  
...  
Keyword(s):  
Aldose Reductase ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor ◽  
Emblica Officinalis ◽  
Isolation And Characterization

scholarly journals Characterization of a Novel Aldose Reductase Inhibitor, TAT, and Its Effects on Streptozotocin-Induced Diabetic Neuropathy in Rats

1993 ◽  
Vol 61 (3) ◽  
pp. 221-227 ◽  
Author(s):  
Shinji Inukai ◽  
Mitsuji Agata ◽  
Manami Sato ◽  
Akira Naitou ◽  
Hidehiko Matsukawa ◽  
...  
Keyword(s):  
Diabetic Neuropathy ◽  
Aldose Reductase ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor

Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat

Metabolism ◽  
1991 ◽  
Vol 40 (1) ◽  
pp. 77-87 ◽  
Author(s):  
Shizuo Ao ◽  
Yasuhiko Shingu ◽  
Chie Kikuchi ◽  
Yukiko Takano ◽  
Kazuhiko Nomura ◽  
...  
Keyword(s):  
Aldose Reductase ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor ◽  
Diabetic Cataract

186-OR: Safety and Tolerability of the Next Generation Aldose Reductase Inhibitor (ARI) AT-001 Supports Initiation of the Pivotal Trial in Diabetic Cardiomyopathy (DbCM)

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 186-OR
Author(s):  
RICCARDO PERFETTI ◽  
FRANCESCA C. LAWSON ◽  
JULIO ROSENSTOCK ◽  
JAMES JANUZZI ◽  
SHOSHANA SHENDELMAN ◽  
...  
Keyword(s):  
Aldose Reductase ◽  
Diabetic Cardiomyopathy ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor ◽  
Pivotal Trial ◽  
Next Generation

462-P: AT-001, a Next Generation Aldose Reductase Inhibitor with Improved Selectivity and Specificity, Protects from Cellular Damage Associated with Hyperglycemia

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 462-P
Author(s):  
RICCARDO PERFETTI ◽  
GAUTHAM YEPURI ◽  
NOSIRUDEEN A. QUADRI ◽  
RAVICHANDRAN RAMASAMY ◽  
AMEEN F. GHANNAM ◽  
...  
Keyword(s):  
Aldose Reductase ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor ◽  
Cellular Damage ◽  
Next Generation

Targeted co-delivery of the aldose reductase inhibitor epalrestat and chemotherapeutic doxorubicin via a redox-sensitive prodrug approach promotes synergistic tumor suppression

2019 ◽  
Vol 7 (7) ◽  
pp. 2889-2906 ◽  
Author(s):  
Venkatesh Teja Banala ◽  
Sandeep Urandur ◽  
Shweta Sharma ◽  
Madhu Sharma ◽  
Ravi P. Shukla ◽  
...  
Keyword(s):  
Aldose Reductase ◽  
Tumor Suppression ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor ◽  
Down Regulation ◽  
Redox Responsive

Redox responsive epalrestat prodrug micelles facilitate synergistic concentrations of doxorubicin with an advantage of CD44 down-regulation and reduced cardiotoxicity.

Sign in / Sign up

Export Citation Format

Share Document